A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

Phase 2 Completed 25 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609

Timeline

Start: 2014-01
Primary completion: 2015-03
Completion: 2015-03

Publications

Hien TT, White NJ, Thuy-Nhien NT, Hoa NT, Thuan PD, Tarning J, Nosten F, Magnusson B, Jain JP, Hamed K. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01940-16. doi: 10.1128/AAC.01940-16. Print 2017 Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cipargamin	Small molecule	10 mg	—
Subject	cipargamin	Small molecule	15 mg	—
Subject	cipargamin	Small molecule	20 mg	—
Subject	cipargamin	Small molecule	30 mg	—

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

Summary

Timeline

Publications

Drugs

Indications